Engineered probiotic shows promise for PKU in small early trial
NCT ID NCT05948020
First seen Feb 27, 2026 · Last updated May 10, 2026 · Updated 8 times
Summary
This early-phase study tested an engineered probiotic (CBT102-A) in 15 children aged 3–17 with phenylketonuria (PKU), a genetic condition that makes it hard to break down an amino acid called phenylalanine. For 20 days, 10 children received the probiotic and 5 received a placebo. The main goal was to see if the probiotic safely lowers blood phenylalanine levels. Because PKU requires lifelong dietary management, this treatment aims to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital of Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.